Update on Management of Acute Migraine

2021 ◽  
Author(s):  
Douglas R. Stayer ◽  
Claire Pearson
Keyword(s):  
Acute Migraine

High-Dose Triptan Advocated for Acute Migraine

2006 ◽  
Vol 39 (3) ◽  
pp. 22
Author(s):  
DAMIAN MCNAMARA
Keyword(s):  
High Dose ◽  
Acute Migraine

Parenteral metoclopramide for acute migraine

2010 ◽  
Author(s):  
Ian Colman ◽  
Grant D Innes ◽  
Michael D Brown ◽  
Ted E Roberts ◽  
Eric Grafstein ◽  
...  
Keyword(s):  
Acute Migraine

Parenteral metoclopramide for acute migraine

2003 ◽  
Author(s):  
Ian Colman ◽  
Grant D Innes ◽  
Michael D Brown ◽  
Ted E Roberts ◽  
Eric Grafstein ◽  
...  
Keyword(s):  
Acute Migraine

Parenteral dihydroergotamine (DHE) for acute migraine

2010 ◽  
Author(s):  
Ian Colman ◽  
Grant D Innes ◽  
Michael D Brown ◽  
Ted E Roberts ◽  
Eric Grafstein ◽  
...  
Keyword(s):  
Acute Migraine

Parenteral corticosteroids for acute migraine

2003 ◽  
Author(s):  
Ian Colman ◽  
Grant D Innes ◽  
Michael D Brown ◽  
Ted E Roberts ◽  
Eric Grafstein ◽  
...  
Keyword(s):  
Acute Migraine

Naratriptan for acute migraine headaches in adults

2013 ◽  
Author(s):  
Sheena Derry ◽  
R Andrew Moore ◽  
Henry J McQuay
Keyword(s):  
Acute Migraine ◽  
Migraine Headaches

scholarly journals Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: The EMPOwER study

Cephalalgia ◽  
2021 ◽  
pp. 033310242110241
Author(s):  
Shuu-Jiun Wang ◽  
Artemio A Roxas ◽  
Bibiana Saravia ◽  
Byung-Kun Kim ◽  
Debashish Chowdhury ◽  
...  
Keyword(s):  
Latin America ◽  
Middle East ◽  
Primary Endpoint ◽  
Episodic Migraine ◽  
Acute Migraine ◽  
Efficacy And Safety ◽  
Medication Treatment ◽  
Significant Difference ◽  
Specific Medication ◽  
Secondary Endpoints

Objective EMPOwER, a double-blind, randomised, phase 3 study, evaluated the efficacy and safety of erenumab in adults with episodic migraine from Asia, the Middle East, and Latin America. Methods Randomised patients (N = 900) received monthly subcutaneous injections of placebo, erenumab 70 mg, or 140 mg (3:3:2) for 3 months. Primary endpoint was change from baseline in monthly migraine days at Month 3. Other endpoints included achievement of ≥50%, ≥75%, and 100% reduction in monthly migraine days, change in monthly acute migraine-specific medication treatment days, patient-reported outcomes, and safety assessment. Results At baseline, mean (standard deviation) age was 37.5 (9.9) years, 81.9% were women, and monthly migraine days was 8.2 (2.8). At Month 3, change from baseline in monthly migraine days (primary endpoint) was −3.1, −4.2, and −4.8 days for placebo, erenumab 70 mg, and erenumab 140 mg, respectively, with a statistically significant difference for erenumab versus placebo (P = 0.002 [70 mg], P < 0.001 [140 mg]). Both erenumab doses were also significantly superior to placebo on all secondary endpoints, including the proportion of patients achieving ≥50% reduction from baseline in monthly migraine days, change from baseline in monthly acute migraine-specific medication treatment days and change from baseline in the Headache Impact Test-6™ scores. The safety profile of erenumab was comparable with placebo; no new safety signals were observed. Conclusions This study of erenumab in patients with episodic migraine from Asia, the Middle East, and Latin America met all primary and secondary endpoints. A consistent numerical benefit was observed with erenumab 140 mg versus erenumab 70 mg across all efficacy endpoints. These findings extend evidence of erenumab’s efficacy and safety to patients under-represented in previous trials. ClinicalTrials.gov identifier: NCT03333109

Sign in / Sign up

Export Citation Format

Share Document